



Published in final edited form as:

Science. 2024 August 02; 385(6708): eadk1679. doi:10.1126/science.adk1679.

## A chemogenetic screen for neuroimmune interplay reveals Trpv1+ neuron control of Tregs in gut

Yangyang Zhu<sup>1,†</sup>, Kimberly A. Meerschaert<sup>1,†</sup>, Silvia Galvan-Pena<sup>1</sup>, Na Ryum Bin<sup>2,3</sup>, Daping Yang<sup>1</sup>, Ryo Kawamoto<sup>1</sup>, Amre Shalaby<sup>1</sup>, Stephen D. Liberles<sup>2,3</sup>, Diane Mathis<sup>1</sup>, Christophe Benoist<sup>1,\*</sup>, Isaac M. Chiu<sup>1,\*</sup>

<sup>1</sup>Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.

<sup>2</sup>Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA.

<sup>3</sup>Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, 02115, USA.

### Abstract

Neuroimmune crosstalk participates in intestinal tissue homeostasis and host defense. However, the matrix of interactions between arrays of molecularly-defined neuron subsets and of immunocyte lineages remains unclear. We utilized a chemogenetic approach to activate eight distinct neuronal subsets, assessing effects by deep immunophenotyping, microbiome profiling and immunocyte transcriptomics in intestinal organs. Distinct immune perturbations followed neuronal activation: Nos1+ neurons regulated Th17-like cells and Chat+ neurons regulated neutrophils. Trpv1+ neurons elicited the broadest immunomodulation, inducing changes in innate lymphocytes, macrophages, and ROR $\gamma$ + T regulatory (Treg) cells. Further neuroanatomical, genetic and pharmacological analysis showed that Trpv1+ neurons in dorsal root ganglia decreased Treg cell numbers via the neuropeptide CGRP. Given the role of these neurons in nociception, these data potentially link pain signaling with gut Treg function.

### One Sentence Summary:

Chemogenetic screen for neuroimmune interactions identifies a role for Trpv1 neurons in controlling ROR $\gamma$ + Treg cells via CGRP.

\*Correspondences to: Christophe Benoist (cb@hms.harvard.edu) and Isaac Chiu (isaac\_chiu@hms.harvard.edu).

†:equal contribution

\*:equal contribution

**Author contributions:** YZ, KAM, IMC and CB conceptualized the study; YZ, KAM, SGP, NRB, DY, RK and AS performed experiments and analyzed data; CB, DM and IMC provided funding; YZ, KAM, IMC and CB drafted the manuscript; all authors reviewed and edited writing.

**Competing interests:** The authors declare no competing interests.

**Data and materials availability:** Data newly reported in this paper are available at the NCBI GEO and SRA repositories under accession number GSE240982.

## INTRODUCTION

The mammalian gastrointestinal (GI) tract is one of the body's critical barrier sites, interfacing for information exchange between the host, nutrients and resident microbiota. A dynamic interplay between the immune system, the nervous system, and microbial ecosystem maintains normal gut physiology and tissue integrity (1-3). The immune and nervous systems both possess exquisitely specific sensing and effector capabilities, and there is great interest in how they can be combined to sense chemical, damaging or infectious threats at the GI frontier.

The GI tract is densely innervated by a complex network of sensory and autonomic neurons. Gut-innervating neurons include the enteric nervous system (ENS), a largely autonomous intrinsic system that coordinates motility and secretion. In addition, extrinsic sensory neurons from dorsal root ganglia (DRG) and nodose ganglia (NG), as well as autonomic neurons that reside in the brainstem and sympathetic ganglia, project to the gut, modulating the activity of the ENS (4-6). DRG and NG neurons function primarily as sensory neurons, possessing multiple receptors such as Piezo2, Transient receptor potential (TRP) channels, and G-protein-coupled receptors (GPCRs) to detect mechanical stretch, dietary and noxious stimuli. Gut-innervating neuronal populations are highly diverse, with many molecular categories identified by single-cell RNA-sequencing (scRNAseq) (7-9). The gut immune system is equally complex, with a representation of immunocytes from all lineages: cells expressing innate receptors that respond immediately to microbial patterns (macrophages (MF) or innate-like lymphocytes (ILCs)), adaptive T or B lymphocytes with tailored responses to antigens on micro-organisms and food, and cell populations whose final role is to dampen inflammation and promote peaceful coexistence with symbiotic microbiota while ensuring barrier integrity and tissue repair (T regulatory cells (Treg), dendritic cells (DCs)).

Several elegant studies in this field have targeted specific neuronal or immunologic subtypes and revealed specific neuro-immune interactions. For example, neurons expressing vasoactive intestinal peptide (VIP) have been shown to modulate the activity of ILC3s (10-12), and Neuromedin U (NMU) expressing enteric neurons amplify ILC2-driven type 2 immune responses (13-15). Sympathetic neurons mediate gut tissue protection by crosstalk with enteric macrophages (16, 17) and ILCs (18). However, beyond these one-to-one interactions, there is a need for a more systematic and integrated approach to identify specific neuro-immune interactions in the gut.

Chemogenetic approaches (19, 20) offer the potential for activation or inhibition of molecularly defined neurons and permit one to probe many such neuronal types in parallel. They rest on the targeted expression of DREADDs (Designer Receptor Exclusively Activated by Designer Drugs), which are engineered GPCRs that are inert except when activated by a synthetic ligand that has no counterpart or receptor in mammalian organisms. Neurons can thus be activated in a temporally controlled manner. If expressed as cell type-specific transgenes, or delivered by viral vectors with fine tropism, they also allow spatial and anatomical targeting. As examples, chemogenetics has allowed the identification of the neural basis of feeding and other behaviors (21-23).

Here, we leveraged an intersectional chemogenetic approach to determine how distinct neurons modulate the gut immune system. We delivered DREADDs to the peripheral nervous system using an adeno-associated virus (AAV) vector with neuron-specific tropism, whose expression was unleashed by Cre recombinase expression in a panel of eight Cre-transgenic mouse lines, chosen to target the major classes of neuronal types that innervate the gut. Following neuronal activation, we analyzed the effects on the gut immune system and microbiota by immunophenotyping, microbial profiling, and single-cell transcriptomics. Activation of distinct neuronal subsets led to discrete alterations in immunocytes. Among these changes, activation of Trpv1<sup>+</sup> neurons had the broadest effects, in particular leading to a decrease in Treg cells in the cecum and colon. We identified the neuro-anatomical basis of this regulation and molecular pathways involved, introducing a new model for neuro-immune collaboration in non-self sensing at the organismal frontier.

## RESULTS

### Chemogenetic screen of neurons for modulatory capacities of the GI immune system and microbiome

We set up a systematic screen to detect how activation of peripheral neuronal subtypes modulate the immune system and gut microbiome, based on targeted expression of DREADD molecules. Our overall strategy was to transduce via an adeno-associated virus (AAV) vector the DREADD-encoding sequence in an inactive configuration, which was unblocked by Cre recombinase expressed in specific neuronal subtypes, and finally activating these targeted neurons by injection of DREADD ligand (Fig. 1A). For expression, we used the AAV.PHP.S viral vector, which efficiently infects peripheral sensory and autonomic neurons in mice without boosting strong immune responses (24). It allows expression of a DREADD and a mCherry fluorescent protein under the human *SYN1* promoter, but only after inversion by Cre recombinase. As a DREADD, we utilized hM3Dq, a muscarinic Gq protein-coupled receptor that had been engineered to respond to the synthetic ligand, clozapine N-oxide (CNO), leading to calcium influx and neuronal activation (25). CNO has a half-life of several hours *in vivo*, such that the neuronal activation was expected to last for several hours. High-titer AAV.PhP.S-hSyn-DIO-hM3Dq-mCherry stocks were injected into neonatal mice, an age which results in higher levels of neuronal labeling compared with adult injections, and avoids immunologic confounders from recent viral infection (26-28).

For neuronal targeting, we chose a panel of 8 transgenic mouse lines expressing Cre in major subsets of peripheral sensory and autonomic neurons that innervate the gut (Table S1). From published scRNAseq datasets (Fig. S1A) and well-defined classical markers of gut innervating neurons (29, 30), we chose the following driver genes: *Chat*, *Nos1*, *Vip*, *Tac1*, *Trpv1*, *Mrgprd*, *Th*, and *Piezo2*. These Cre lines (31-38) were chosen to label intrinsic neurons of the enteric nervous system (*Chat-cre*, *Nos1-cre*, *Vip-cre*, *Tac1-cre*), sensory neurons in the vagal jugular/nodose ganglia (NG, *Trpv1-cre*, *Vip-cre*, *Nos1-cre*, *Piezo2-cre*, *Tac1-cre*, *Th-cre*), and sensory neurons in the dorsal root ganglia (DRG, *Trpv1-cre*, *Tac1-cre*, *Mrgprd-cre*, *Piezo2-cre*, *Th-cre*, *Nos1-cre*) (Fig. 1B). The *Th-cre* and *Chat-cre* lines also target postganglionic sympathetic neurons and parasympathetic neurons,

respectively. To confirm expression of the DREADD in neurons of the injected mice, we stained sections of the NG, DRG and the ENS myenteric plexus (MP) in the colon with antibodies against the pan-neuronal marker Beta-III Tubulin (Tuj1) and mCherry (Fig. 1C). The NG and DRG showed labeling of mCherry+ neuronal cell bodies, while the colon showed both ENS cell bodies and fibers that may represent either intrinsic or extrinsic innervation. Quantification of mCherry expression out of total Tuj1+ neurons in each Cre line showed expression in the DRG, NG or MP that fit expected patterns for the transgenic markers (Fig. 1D), with frequencies of labeling close to, but lower than those expected from known marker or reporter expression. The only exception was *Mrgprd-creErT2* mice, which required tamoxifen injection for Cre induction and for which mCherry expression was distinctly present but less than expected, possibly because of low or mis-timed Cre expression. Overall, this intersectional chemogenetic approach eschewed non-neuronal DREADD expression and limited it to targeted expression within neurons, in a sizeable proportion but not necessarily in every neuron, which may be an advantage for the functional experiments.

### DREADD-based activation of specific neurons elicits distinct changes in gut immunocyte pools

After confirming the specificity and efficiency of this AAV.PhP.S<sup>hM3Dq</sup> Cre-based activity, we investigated the changes within intestinal populations of immunocytes induced by chemogenetic activation of various neurons. Mice were infected neonatally with AAV.PhP.S<sup>hM3Dq</sup>, and treated at adult age with CNO (hereafter abbreviated as “ADC” mice) every other day over a two week period. Lymphoid and myeloid cells from different intestinal locales (ileum, cecum, colon) were then analyzed by high-parameter flow cytometry (31 immunophenotypes altogether, staining panels and gating strategies in Fig. S2A). For robustness, each experiment included ADC mice and matched Cre-negative littermates also AAV-injected and CNO treated (hereafter CTRL).

Overall, a number of neuro-immune relationships were detected by this screen, where the chemogenetic activation of a given neuronal subset led to distinct changes in immunophenotypes (illustrated in Figs 2A-F, tabulated in Fig. 2G). Some relationships were very exclusive. *Nos1*+ nitrergic neuron activation specifically downregulated ROR $\gamma$ + CD4+ T conventional (Th17-like) cells in the ileum compared to CTRLs (Fig. 2A), whereas *Chat*+ cholinergic neuron activation downregulated ileal neutrophils (Fig. 2B). *Mrgprd*+ neuron activation led to increased ileal populations of MHCII+ mononuclear phagocytes (MNP) (Fig. 2C). These three effects were specific to the ileum, with no corresponding counterpart in the cecum or colon (Fig. S2B-D). By contrast, activation of *Trpv1*+ sensory neurons affected several cell populations: ILC2s in the colon (Fig. 2D), and ROR $\gamma$ + Treg cells in both the colon and cecum (Fig. 2E, F), but also total colonic Tregs, colonic macrophages (significantly but more modestly) and the CD44+ fraction of colonic CD8+ T cells (Fig. 2G, Fig. S2E-G and Fig. S3). In contrast, some immunocyte populations were not affected by activation of any neuronal subtypes tested (B,  $\gamma\delta$ T, and NK cells; Fig. 2G, Fig. S2H-J). Conversely, activation of some neurons (*Piezo2*, Th or VIP) seemed without influence on the homeostatic setting of gut immunocytes (Fig. 2G). Neuronal types that had effects on immunocyte populations were found among the various origins of intestinal

innervation (NG, DRG or ENS – Fig. 1B). Thus, the screen uncovered a patchwork of discrete alterations induced by chemogenetic activation of distinct neuronal types, with Trpv1+ nociceptor neurons having the most widespread effects.

### DREADD-based neuronal activation induces modest changes in the gut microbiota

Many situations have been described in which alterations in gut microbes influence the peripheral nervous system (1, 39, 40), and a few cases where perturbations of gut-innervating neurons reflect on the intestinal microbiota (41, 42). We asked whether the specific neuronal activation we were eliciting in ADC mice provoked strong dysbiosis (which could be a confounder for the interpretation of the immunophenotypes observed), or rather more specific effects on a microbial family or genus. Bacterial populations were profiled in colonic content from ADC and CTRL littermates by 16S rDNA amplification and sequencing (testing littermate pairs to eschew cage-of-origin issues). There was no indication of strong dysbiosis in any of the mice, as  $\alpha$ -diversity in ADC and CTRL littermates was generally comparable, except for a few of the Trpv1-ADC mice (Fig. 3A; these mice with lower diversity did not have particularly low colonic ROR $\gamma$ + Tregs or other immunologic changes). Similarly, principal components analysis showed no marked deviation between ADC and CTRL littermates (both CNO-treated), except for some of the mice in the Trpv1-ADC and Tac1-ADC groups (Fig. 3B). Closer examination at the phylum level showed a modest but significant increase in the abundance of Bacteroidetes in Trpv1-ADC (with a corresponding decrease in Firmicutes (Fig. 3C), of interest because Zhang et al showed that disruption of intestinal Trpv1 innervation led to an increase in Bacteroidetes (42). This deviation in Bacteroidetes/Firmicute balance was confirmed in a replication cohort of Trpv1-ADC mice (Fig. 3D). On the other hand, analysis of finer taxonomic ranks failed to reveal significant changes in ADC mice beyond the level of experimental noise (estimated by iterative permutation) or that were reproducible in the replication cohort (the sole exception was a 25-fold increase in abundance of *Clostridiaceae* in Tac1-ADC mice; Table S3). Thus, activation of the wide range of intestinal neuronal types in our panel did not induce large reorganization of the gut microbiota, beyond modest shifts in phylum representation.

### Trpv1+ neurons control the gut Treg niche

Among the different “hits” brought forth by our screen of immunologic changes following neuronal chemogenetic activation, we opted to focus deeper analyses on the reduction in ROR $\gamma$ + Treg cells resulting from activation of Trpv1+ neurons, which mediate nociception of noxious heat and capsaicin (43) and mainly reside in the DRG and NG. This phenotype was robust and reproducible (Fig. 2), and ROR $\gamma$ + Tregs are a particularly interesting population of immunoregulatory cells (44). Their frequencies are modulated by gut microbes, they help control tissue inflammation, oral tolerance, and maintain peaceful co-existence at the host/symbiont interface (44, 45). Most germane to the present study, we demonstrated previously that the control of ROR $\gamma$ + Tregs by gut microbes is associated with perturbations of the ENS, proposing a triangular interaction between gut microbes, ROR $\gamma$ + Tregs and the intestinal nervous system (46, 47), and a vagal brain-gut arc has also been proposed to maintain gut Tregs (48). ROR $\gamma$ + Treg cells result, in a large part, from conversion of FoxP3-negative T conventional cells (Tconv) in the intestinal lymphoid

tissues, but there is some debate whether this conversion takes place in the draining lymph nodes or in the lamina propria. Here, the effect of Trpv1+ neuron activation was visible in the lamina propria, but not in the mesenteric lymph nodes (mLN) (Fig. 4A), as was the reduction in total Treg cells, suggesting that the impact of neuronal activation was playing out in the intestinal wall itself, not in the draining lymph nodes. Interestingly, we also noted a significant reduction of ROR $\gamma$ + Tregs in the spleen of Trpv1-ADC mice. Although far less abundant than in the colon, recent results support the notion that these small pools share many characteristics of ROR $\gamma$ + Treg cells in the colon, and result from trafficking from the gut to the systemic lymphoid organs (49-51). Thus, the consequences of neuro-immune interactions in the gut seem to be reflected more systemically.

A new class of unconventional antigen presenting cells, Thetis/Janus cells were identified recently and shown to control ROR $\gamma$ + Treg frequencies (52, 53). In the mLNs of Trpv1-ADC mice, we did not detect significant changes in MHCII+IL7R-CXCR6- cells after activation (Fig. S4A), indicating that Thetis/Janus cells are not an intermediate for Trpv1-ADC effects. As a next step in elucidating the mechanism that connects Trpv1+ neuron activation and ROR $\gamma$ + Tregs we determined the kinetics of the response: was the drop on ROR $\gamma$ + Tregs a fast response, or did it represent a longer-lasting change in homeostatic setpoints? The frequencies of ROR $\gamma$ + Tregs were not affected one day after CNO treatment, excluding a rapid response. Some Trpv1-ADC mice began showing a drop after one week, but the fully significant decrease in ROR $\gamma$ + Tregs was not evident until two weeks of activation (Fig. 4B), suggesting a slow adaptation. On the other hand, the drop in ROR $\gamma$ + Treg frequencies did not represent a stably altered setpoint: three weeks after cessation of treatment, the frequencies had reverted back to normal (Fig. 4C).

In principle, this slowly unfolding drop in colon and cecum ROR $\gamma$ + Tregs could be due to induced extravasation from the gut, cell death, and/or decreased proliferation from a reduced niche size. To assess the turnover of intestinal Tregs, we bred *Trpv1-Cre* mice with transgenic mice encoding the photoconvertible Kaede fluorescent protein (54). In Kaede mice, colon cells can be temporarily switched from green to red by colonoscopic illumination with violet light, and both their residence in the colon and emigration into systemic organs tracked over time (49, 50, 55). In Trpv1-ADC mice, CNO treatment slightly lowered the proportion of photoconverted cells remaining in the descending colon after 24 hours, a trend that affected essentially all cell-types, not specifically ROR $\gamma$ + Tregs (Fig. 4D); CNO treatment did not alter photoconversion efficiency. This result indicated that Trpv1+ neuron activation slightly increased immunocyte turnover in the colon, but was unlikely to account for the specific effect on ROR $\gamma$ + Tregs. Annexin-V staining showed that there was no increase in the proportion of dying cells as a result of neuronal activation (Fig. S4B). Finally, an effect on Treg proliferation was assessed by staining for the nuclear factor Ki67. Ki67 has a complex relationship with the cell cycle, being actively synthesized during S, G2 and M phases, then progressively degraded during G1 and G0, serving as a marker of the time since the last division (56). Here, Tregs in Trpv1-ADC mice showed slightly decreased proportion of Ki67<sup>hi</sup> ROR $\gamma$ + Tregs as their CTRL littermates (Fig. 4E), and a shift was noted in the noncycling peak, which lost Ki67 intensity in ROR $\gamma$ + Tregs but not in other lymphocytes (Fig. 4F). These results suggest that Trpv1+ nociceptor neuron activation

decreases the ROR $\gamma$ <sup>+</sup> Treg pool not by cell death but by curtailing the proportion of Tregs that are poised to enter the cell cycle.

Colonic Treg cells contribute to maintaining gut barrier integrity and to regulating immunopathology (44). Thus, we interrogated whether Treg downregulation induced by Trpv1<sup>+</sup> neuron activation had functional consequences. To this end, at the end of the two-week activation period by CNO treatment, we fed mice Dextran Sodium Sulfate (DSS) to induce colitis. Trpv1-ADC mice displayed more severe weight loss than did their CTRL littermates, not during the initiation phase but during the recovery phase (Fig. S5A), with higher inflammation by histology (Fig. S5B). We also infected mice with *Citrobacter rodentium*, an attaching/effacing bacterial pathogen that induces colon inflammation and pathology in mice (57). Trpv1-ADC mice lost more body weight than the controls (Fig. S5C). In addition, even though their gut colonization with *C. rodentium* was comparable with that of controls (Fig. S5D), many of the Trpv1-ADC mice showed systemic dissemination of the bacterium to the spleen and liver (Fig. S5E). Thus, nociceptor neuron activation not only resulted in decreased levels of ROR $\gamma$ <sup>+</sup> Tregs, but affected proper inflammatory responses in various models.

### Transcriptome changes in immunocytes resulting from Trpv1<sup>+</sup> neuron activation

Having observed the effects of sensory neuron activation on colonic Treg cells, and as a first step towards elucidating the functional connection, we explored more generally the changes in the intestinal ecosystem that might explain this observation. Overall, histological analysis revealed no striking change in the general architecture of the colon, with no inflammatory infiltrate or tissue destruction (Fig. S6A). The overall architecture of the MP did not show major distortion in Trpv1-ADC mice, as evidenced by Tuj1 staining (Fig. S6B). These results indicated that Trpv1<sup>+</sup> neuron activation did not grossly affect the immunologic or neurologic architecture in the colon.

To investigate possible intermediate events between Trpv1<sup>+</sup> neuron activation and changes in ROR $\gamma$ <sup>+</sup> Tregs, we performed single-cell RNA sequencing (scRNAseq) on total CD45<sup>+</sup> immunocytes from the cecum of Trpv1-ADC and CTRL mice (in biological duplicates). Dimensionality reduction and projection on a Uniform Manifold Approximation and Projection (UMAP) revealed all the common immunologic lineages expected in the cecum, including T and B lymphocytes, ILCs and myeloid cells (Fig. 5A), identifiable by the usual specific transcripts (Fig. S7A), with equivalent distributions in all four mice profiled (Fig. S7B). Comparing the relative density of cells from Trpv1-ADC and CTRL mice revealed shifts in some immunocyte populations, most markedly in lymphoid cells, less so in myeloid cells (Fig. 5B). To identify the immunocyte transcripts perturbed by Trpv1<sup>+</sup> neuron activation, while avoiding those appearing differential merely because of altered cell-type representation, we performed Differential Gene Expression analysis separately on individual cell populations, tallying the resulting most affected 187 transcripts on the heatmap of Fig. 5C (Table S4; statistical significance of the clusters is shown on the volcano plots of Fig. S7C). These data illustrate a diversity of effects of Trpv1<sup>+</sup> neuron activation on immunocytes, generally mild but broader than we initially realized from the immunophenotyping, many cutting across cell-types. This breadth was particularly true of

gene cluster c1, induced in almost all cell-types, which was almost exclusively composed of heat-shock proteins and other stress response genes (*Hspa1a/b*, *Hsp8*, *Hsp90*, *Dnajb1*), suggesting that immunocyte stress resulted from Trpv1+ neuronal activation. To ask whether Hsp induction reflected a general cell stress, we analyzed the distribution of transcripts of a prototypical signature of cell damage (58). Only a minority of these transcripts was upregulated (Fig. S7D), indicating that the stress response to neuron activation had specificity, and was not merely uncontrolled cell damage. Two other clusters (c4, c5) were most prominently altered in intraepithelial lymphocyte (IEL)-like T cells, but also in other cell-types, and formed a network enriched ( $p=10^{-4}$  to  $10^{-6}$ ) in cytokine receptors (*Tnfrsf1*, *Il21r*, *Ifngr1*), cell signaling (*Lyn*, *Itk*, *Map3k1*) and transcriptional regulators centered around *Nfkb1*, *Stat3* and *Stat4* (Fig.S7E), suggesting that neuronal activation might have tuned inter-cellular communication between immunocytes.

To analyze more closely the changes occurring in Treg cells of Trpv1-ADC mice, we recomputed a UMAP focused on Treg cells alone, which clearly identified ROR $\gamma$ +, Helios+ and DN Treg cells (Fig. 5D) substantiated by the expression of signature genes (59) (Fig. S7F). Many of the changes seen in Tregs in the wider analysis of Fig. 5C were observed in both ROR $\gamma$  and Helios Tregs (e.g. the induction of heat-shock proteins, or the downregulation of *Lmna* or *S100a6* - Fig. S7G) suggesting that they may not themselves discriminate between Treg subsets. A comparative density plot revealed a focused reduction that affected only a segment of the ROR $\gamma$ + Treg group (“A” cluster in Fig. 5E), but not the other (“B”). We asked what genes might distinguish, in CTRL mice devoid of induced neuronal activation, the “A” ROR $\gamma$ + Tregs destined to be reduced electively by Trpv1+ neuron signaling, relative to their more resistant “B” counterparts (Fig. 5F). Interestingly, several of the differential transcripts revealed by this comparison within CTRL Treg subsets belonged to those further altered by Trpv1+ neuron activation (*Hsp* family, Table S5). This observation suggests that the programmatic changes in ROR $\gamma$ + T reg cells that could be altered or induced by neuronal activation were already in play in SPF mice at steady state.

### Trpv1+ spinal afferent neurons are responsible for altering the Treg niche

After characterizing the immunocyte changes induced by activation of Trpv1+ neurons, we next aimed to determine the neuronal mechanisms that led to Treg modulation. Trpv1 is expressed in two main anatomical locations, DRG neurons that centrally project to the spinal cord and NG neurons that project via the vagus nerve to the brainstem (8, 9) (Fig. S1B). Given that our chemogenetic strategy would label and activate all of these neurons, it was important to determine the relative contribution of the two Trpv1+ neuron locations in controlling gut Treg populations, adopting a strategy of AAV9 mediated delivery of Cre-dependent reporters into NG by intranodose injections or to the DRG via intrathecal injections (60, 61).

To target Trpv1+ neurons in the NG, we performed bilateral intranodose injections of AAV9<sup>hM3Dq</sup> virus in *Trpv1-cre* mice or control littermates (Fig. 6A). Intranodose injection yielded robust DREADD-mCherry expression in NG neurons, with no labeling of DRG neurons (Fig. 6B). In these mice, chemogenetic activation by CNO treatment did not elicit changes in colonic ROR $\gamma$ + Tregs or any other immunocyte populations relative to CTRL



littermates (Fig. 6C, S8A). We next performed intrathecal injections of AAV9<sup>hM3Dq</sup> virus into the lumbar spinal column of *Trpv1-cre* mice or control littermates (Fig. 6D). Intrathecal injection resulted in specific expression of DREADD-mCherry in DRG neurons but not vagal neurons (Fig. 6E). Chemogenetic activation of DRG Trpv1<sup>+</sup> neurons by 2-weeks of CNO treatment resulted in a significant decrease in cecal and colonic ROR $\gamma$ <sup>+</sup> Tregs and macrophages in intrathecally injected mice, suggesting that DRG Trpv1<sup>+</sup> neurons modulated multiple immunocyte populations as we observed for whole body Trpv1<sup>+</sup> neuron activation (Fig. 6F, S8B). Together, these data indicate that activation of sensory Trpv1<sup>+</sup> neurons in the DRG, but not of vagal neurons, was sufficient to induce Treg population changes in the GI tract.

We next determined, in loss-of-function experiments, if DRG neurons were necessary for Trpv1<sup>+</sup> neuronal regulation of Tregs. As above, we generated Trpv1-ADC mice, in which we performed targeted ablation of DRG Trpv1<sup>+</sup> neurons by intrathecal injection of resiniferatoxin (RTX), a high affinity Trpv1 agonist that causes the loss of Trpv1<sup>+</sup> neurons (62) (Fig. 6G). Mice treated with intrathecal injection of RTX had greatly diminished DREADD-mCherry expression in the DRG, while sparing those neurons in the NG (Fig. 6H). Following chemogenetic activation by CNO-treatment, Trpv1-ADC mice treated with RTX lost the downregulation of cecal and colonic ROR $\gamma$ <sup>+</sup> Tregs observed in the Trpv1-ADC mice (Fig. 6I).

Taken together, we demonstrated that activation of Trpv1<sup>+</sup> neurons in the DRG was necessary and sufficient to induce a decrease in ROR $\gamma$ <sup>+</sup> Tregs. By contrast, activation of Trpv1<sup>+</sup> vagal neurons did not affect this population. A previous study had reported that vagotomy and capsaicin injections into the vagus nerve altered colonic Treg populations and proposed a brain-liver-gut sensory-autonomic circuit (48). However, our data indicates that spinal DRG Trpv1<sup>+</sup> neurons but not vagal neurons played a critical role in regulating ROR $\gamma$ <sup>+</sup> Tregs in the context of repeated nociceptor activation.

### Trpv1<sup>+</sup> neurons regulate the gut Treg niche through a CGRP-Ramp1 axis

After determining the location of the Trpv1<sup>+</sup> neurons responsible for decreasing ROR $\gamma$ <sup>+</sup> Treg frequencies, we wanted to elucidate the mechanism through which these neurons signal to the Treg cells. In principle, this regulation could be via direct neuroimmune communication and/or indirectly via an intermediate cell-type. Trpv1<sup>+</sup> neurons in the DRG are peptidergic (63), expressing neuropeptides including calcitonin-gene related peptide (CGRP) and Substance P (SP) (Fig. S9A - [mousebrain.org](http://mousebrain.org)). Given the role of these neuropeptides in regulating both vascular and immune responses in neurogenic inflammation (64), we hypothesized that Trpv1<sup>+</sup> neurons might release neuropeptides upon activation that could signal to and impair ROR $\gamma$ <sup>+</sup> Treg turnover. Substance P is encoded by *Tac1*, which can also be spliced to encode neurokinins A and B (65). We intercrossed *Tac1*<sup>-/-</sup> with *Trpv1-cre* mice to generate Tac1-deficient Trpv1-ADC mice. In these animals, the reduction in total ROR $\gamma$ <sup>+</sup> Tregs in the colon following CNO treatment was similar to that of Trpv1-ADC mice (Fig. 7A), suggesting that SP and neurokinins were not required. Similarly, macrophage and ILC2 populations were still reduced in Trpv1-ADC mice (Fig. S9B), indicating that SP is not essential for effects of neuronal activation in this model.

CGRP is expressed by two genes, *Calca* (encodes CGRP $\alpha$ ) and *Calcb* (CGRP $\beta$ ), whose products both bind to the same receptor complex and have similar functional activity (66). *Calca* is expressed at higher levels in DRG than enteric neurons, while *Calcb* is expressed in both DRG and enteric neurons (7, 66). Given our finding that DRG nociceptors regulated Tregs (Fig. 6), we next crossed *Trpv1-Cre* mice with *Calca*<sup>-/-</sup> mice to deplete CGRP $\alpha$ . *Calca*<sup>-/-</sup> *Trpv1-ADC* mice did not show the usual decrease in colonic and cecal ROR $\gamma$ <sup>+</sup> Tregs compared with CTRL littermates treated with CNO (Fig. 7B), indicating an important role for CGRP $\alpha$  in nociceptor/Treg crosstalk. However, the macrophage compartment was still downregulated (Fig. S9C), denoting a specific involvement of CGRP $\alpha$  in neuronal regulation of Tregs.

CGRP has been reported as a mediator in neuro-immune interactions (67, 68) involving several immunocytes of the innate immune system like ILC2s (69-71), neutrophils (72, 73) or dendritic cells (74). These raised the possibility that the effect of *Trpv1*<sup>+</sup> neuron activation was indirect, via one of these cells as intermediates (in line with observations in the injured muscle, where neuronal CGRP tunes IL-33 production by mesenchymal stromal cells, and hence the accumulation of muscle Tregs (75). Interestingly, immunofluorescence analysis on whole-mounts of normal colon tissue showed distinct proximity between FoxP3<sup>+</sup> Treg cells and CGRP-positive fibers of sensory neurons in the lamina propria, consistent with the notion that these cells might directly interact (Fig. 7C). To further test this hypothesis, we asked whether the CGRP receptor on Treg cells was required for the *Trpv1-ADC* effect. CGRP acts on target cells by binding to a high-affinity receptor complex formed by CALCRL and modifying co-receptor RAMP1 (66) (Fig. 7D). In the scRNAseq data, *Ramp1* was preferentially expressed in ROR $\gamma$ <sup>+</sup> Tregs, relative to Helios<sup>+</sup> Tregs, providing a possible explanation for a preferential effect of *Trpv1-ADC* on ROR $\gamma$ <sup>+</sup> Tregs (Fig. 7E). To assess whether the RAMP1 receptor is indeed required for *Trpv1*<sup>+</sup> neuronal signaling to Tregs, we treated mice with the RAMP1 antagonist BIBN4096 (76) or vehicle one hour before every CNO injection in *Trpv1-ADC* mice or CTRL littermates. This pre-treatment reverted the action of neuronal activation, showing that RAMP1 blockade rescued the decrease in ROR $\gamma$ <sup>+</sup> Tregs resulting from *Trpv1*<sup>+</sup> neuron activation (Fig. 7F). In addition, we generated *Ramp1*-deficient Tregs by crossing the *Ramp1*<sup>fl/fl</sup> conditional allele with *Foxp3-Cre* mice (in addition to *Trpv1-cre*), to ablate *Ramp1* in Treg cells (because of the two Cre transgenes in these mice, *Ramp1* is also deleted in *Trpv1*<sup>+</sup> neurons, which should be irrelevant). These *Foxp3-creRamp1*<sup>fl/fl</sup> *Trpv1-ADC* mice did not show the usual decrease in colonic ROR $\gamma$ <sup>+</sup> Tregs following CNO treatment (Fig. 7G). Macrophage and ILC2 populations were still downregulated (Fig. S9D). These data together suggest that CGRP $\alpha$  released from *Trpv1*<sup>+</sup> neurons upon neuronal activation bound to the RAMP1/CALCRL receptor complex on ROR $\gamma$ <sup>+</sup> Tregs, affecting their homeostatic control. Thus, several independent clues demonstrated that CGRP was the mediator from activated neurons that exerted their negative control on ROR $\gamma$ <sup>+</sup> Treg cells.

## DISCUSSION

The nervous and immune systems jointly regulate tissue homeostasis and physiology at the main interface with the microbiota in the gut, each bringing into play wide constellations of cell-types of varied phenotypes and functions. Gut-extrinsic and intrinsic neurons influence

the homeostasis of particular populations of immunocytes (47, 77-81), but we lacked an integrated understanding of how the panels of neurons and immunocytes interact. Here, we leveraged chemogenetic activation of distinct neuronal subsets to determine effects on immunocyte populations and the gut microbiota. The results highlight a number of individual neuroimmune connections. Trpv1+ neuron activation induced the most robust changes in immunocyte populations, in particular the reduction in Treg cells. We further investigated this interaction using neuroanatomical and molecular approaches, finding that spinal afferent Trpv1+ neurons mediated Treg changes via the neuropeptide CGRP. Given that these neurons mediate visceral pain, these data reveal a potential crosstalk between pain signaling and immune regulation in the gut.

Several recent studies have described the relationship between particular neuronal subsets and immunocytes in the gut (10-12, 14, 16-18, 71, 82-86). The present work extends by providing a more extensive and integrated view of neuroimmune interactions of relevance to the gut, by leveraging a panel of neuron subtype-specific DREADDs. We must acknowledge that there is a degree of artificiality in the approach, as it involves coordinated GPCR-induced activation, extending in a number of body locations. However, we chose our experimental design (repeated activation over a two-week period, instead of a single high-intensity burst) because it might reveal effects occurring over time, and mimic conditions encountered in diseases where peripheral neurons are chronically activated, such as in chronic visceral pain, autonomic imbalance, or GI dysmotility (87-89).

We uncovered several neuron-immunocyte interactions that pointed to a broader involvement of neuronal types than had been hitherto recognized, and will make for fascinating future explorations. Nitroergic (Nos1+) enteric neurons produce nitric oxide and mainly play an inhibitory role in peristalsis (90); their activation reduced the proportion of Th17-like ROR $\gamma$ + Tconv cells in the ileum, possibly indicating a coordinated regulation of motor activity and Type-3/17 immune responses. Conversely, cholinergic (Chat+) excitatory motor neuron activation decreased neutrophils in the ileum. It remains to be determined if this finding relates to the cholinergic anti-inflammatory reflex, which was defined as acting through Chat+ vagal neurons that operate through macrophages and T cells in the spleen (91, 92). As these immunocytes are functionally related in host defense (e.g. Th17 and neutrophils), and these neuronal subsets coordinate motor function and peristalsis, one might speculate that motility and effector T cell responses might be coordinated. Mrgprd+ sensory neuron activation boosted the proportion of MHCII<sup>hi</sup> MNPs in the ileum. Mrgprd+ neurons suppress mast cell activation through glutamate in the skin (93), but the role of Mrgprd+ neurons in the gut is less well understood.

Amidst this diversity, Trpv1+ nociceptors were clearly those whose activation elicited the broadest and most robust changes, not only altering the gut ROR $\gamma$ + Treg niche, but also ILC2s, macrophages, and activated CD8+ T cells (Fig. 2G). Transcriptome profiling revealed changes in an even broader set of immunocytes resulting from Trpv1+ neuron activation. The most general effect was the increased expression of heat-shock and other stress response genes in most cell types, suggesting that signals from activated nociceptor neurons are interpreted as stress signals by immunocytes (Fig. 5C). Importantly, this induction did not include most of the transcripts of the generic van Oudenaarden signature of

“cell suffering” (58), indicating some specificity to the stress signals involved, and arguing against experimental artefacts. In addition, the expression of this stress signature was more pronounced in normal mice at steady state in the targets of Trpv1 neurons, suggesting that this mode of regulation operates at baseline, independent of experimental manipulation.

Why did Trpv1+ neuron activation cause the broadest immunocyte changes among the neurons subtypes we probed? Trpv1+ neurons, as a subset of nociceptors whose primary function is to detect and transmit noxious signals to the central nervous system, are sensitized by a variety of inflammatory mediators, and nociceptors can activate the immune system through neurogenic inflammation (64). Correspondingly, several reports have already described isolated interactions between immunocytes and Trpv1+ sensory neurons. In the skin, Trpv1+ neurons interact with IL23-producing DCs and are required for Imiquimod-induced dermatitis (94), and their optogenetic activation can trigger Th17 responses in the skin, setting the stage for defense against fungal and bacterial pathogens (95). Trpv1+ neurons have also been shown to have inhibitory influence over immunocytes. In bacterial skin and lung infections, Trpv1+ neurons suppress neutrophil recruitment and myeloid cell responses to *Streptococcus pyogenes* and *Staphylococcus aureus* (72, 73). Conversely, Th17 cells induced by skin commensals promote sensory neuron regeneration during wound healing through IL17 receptor expressed on these neurons (96), indicating that the interface is bidirectional. Overall, the dominance of Trpv1+ neurons in neuroimmune crosstalk makes sense, if one considers the nociceptive nervous system and immune systems as sensory organs that constantly monitor the environment for danger and mediate inflammation: tight communication between these sentinels would seem important.

Emerging evidence also connects Treg cells to pain modulation. CD4+ T cells can signal to nociceptors mediating an anti-nociceptive role. In inflammatory models of chronic somatic pain measured in the footpad (97-99), as well as in DSS-colitis-induced visceral pain in the gut (100), T cell depletion caused prolonged pain hypersensitivity. Treg specific depletion with anti-CD25 treatment (101) or in Foxp3-DTR mice (102) led to increased mechanical hypersensitivity and neuropathic pain in sciatic nerve injury. Thus, Tregs seem to play a protective role in pain, likely through release of anti-inflammatory cytokines such as IL10 and production of endogenous opioids including proenkephalin, which can act directly on nociceptors to block pain; inhibition of proinflammatory immune cells can also indirectly lead to decreased pain (101-104). In the present study, persistent Trpv1+ nociceptor activation induced a decrease of Tregs, which we speculate might represent an adaptation, the dampening of a negative feedback loop in the face of an unresolved noxious stimulus, leading to prolonged or enhanced chronic pain. Thus, nociceptors and Tregs may have bidirectional communication and imbalance of this communication may be important in the development and maintenance of chronic pain.

The biogeography and neural circuitry of neuroimmune interactions in the gut remains a poorly understood topic. Neural tracing studies have shown that vagal ganglia innervation decreases in the lower GI tract (29), whereas DRG spinal afferent neurons innervate the entire GI tract (4). Our data show that DRG but not vagal neurons regulate colonic and cecal Tregs. This signaling is likely through local secretion of CGRP, but we cannot rule out the possibility that Trpv1+ neurons also signal through a neural reflex arc through the

CNS, although not through a previously proposed vagal route (48). DRG sensory neurons have central terminals and reflex circuits in the spinal cord, and more complex circuits in higher cortical areas. Recent work has mapped CNS regions linked to mouse models of gut inflammation including DSS induced colitis and food allergies (105-107). It would be interesting to determine if such brain regions are also connected with peripheral neuron subsets that actively regulate immunity in the gut.

Overall, our study used a DREADD-based in vivo neuronal activation system to discover a number of neuro-immune interactions that control and modify immunocyte populations in the gut, and demonstrate a role for Trpv1+ neurons in modulating gut Tregs via CGRP-Ramp1 signaling. These observations raise the intriguing possibility that the nervous and immune systems, with their molecularly different sensory modalities, cooperate towards a balanced response to potentially noxious challenges in the digestive tract.

## Materials and Methods

### Mice

We utilized aged matched 6- to 12-week-old littermate male and female mice for all experiments. C57BL/6J (B6), B6;129S6-*Chat*<sup>tm2(cre)Lowl/J</sup> (Chat-Cre), B6.129-*Trpv1*<sup>tm1(cre)Bbm/J</sup> (Trpv1-Cre), B6.129-*Nos1*<sup>tm1(cre)Mgmj/J</sup> (Nos1Cre), *Vip*<sup>tm1(cre)Zjh/J</sup> (Vip-Cre), B6.Cg-*7630403G23Rik*<sup>Tg(Ther)1Tmd/J</sup> (Th-Cre), *Mrgprd*<sup>tm1.1(cre)ERT2)Wql/J</sup> (Mrgprd-CreER), B6; 129S-*Tac1*<sup>tm1.1(cre)Hze/J</sup> (Tac1-Cre), B6(SJL)-*Piezo2*<sup>tm1.1(cre)Apat/J</sup> (Piezo2-Cre), B6.129-*Gt(ROSA)*<sup>26Sortm1(CAG-CHRM4\*, -mCitrine)Ute/J</sup> (R26-hM4Di/mCitrine), B6.129(Cg)-*Foxp3*<sup>tm4(YFP/cre)Ayr/J</sup> (FoxP3-CreYFP), and B6.Cg-Tac1<sup>tm1Bbm/J</sup> (*Tac1*<sup>-/-</sup>) mice were purchased and obtained from the Jackson Laboratory (Bar Harbor, Maine) and bred in the specific-pathogen free animal facility at Harvard Medical School (HMS). B6.129S6-*Calca*<sup>tm1Hku</sup> (*Calca*<sup>-/-</sup>) (108) mice were kindly provided by Vijay Kuchroo (Harvard Medical School). *Ramp1*<sup>tm1a(EUCOMM)Wtsi/H</sup> (*Ramp1*<sup>flox/flox</sup>) mice were purchased from the European Mouse Mutant Archive (EMMA). Kaede transgenic (Kaede) mice were originally obtained from O.Kanagawa (RIKEN, Wako, Japan). Trpv1-Cre, Chat-Cre, Nos1-Cre, Vip-Cre, Th-Cre, Mrgprd-CreER, Tac1-Cre, Piezo2-Cre mice were crossed with B6 mice to generate Trpv1-Cre<sup>+/-</sup>, Chat-Cre<sup>+/-</sup>, Nos1-Cre<sup>+/-</sup>, Vip-Cre<sup>+/-</sup>, Th-Cre<sup>+/-</sup>, Mrgprd-CreER<sup>+/-</sup>, Tac1-Cre<sup>+/-</sup>, Piezo2-Cre<sup>+/-</sup> and littermate control mice to use for subsequent AAV-based experiments outlined below. For analysis of immune migration, Trpv1-Cre<sup>+/-</sup> mice were crossed with Kaede mice to generate Trpv1-Cre<sup>+/-</sup>-Kaede and Trpv1-Cre<sup>-/-</sup>-Kaede mice. For assays related to the role of neuropeptides in immunity, Trpv1-Cre mice were crossed with *Tac1*<sup>-/-</sup> or *Calca*<sup>-/-</sup> to generate Trpv1-Cre<sup>+/-</sup> *Tac1*<sup>+/-</sup> or Trpv1-Cre<sup>+/-</sup> *Calca*<sup>+/-</sup> mice, and F1 heterozygotes further crossed to *Tac1*<sup>+/-</sup> or *Calca*<sup>+/-</sup> mice to generate Trpv1-Cre<sup>+/-</sup> *Tac1*<sup>-/-</sup> or Trpv1-Cre<sup>+/-</sup> *Calca*<sup>-/-</sup> mice and littermate controls, respectively. For Treg specific deletion of Ramp1, which is the co-receptor for CGRP, FoxP3-CreYFP mice were crossed with *Ramp1*<sup>flox/flox</sup> mice. FoxP3-CreYFP-*Ramp1*<sup>flox/flox</sup> mice were then crossed with Trpv1-Cre mice to generate Trpv1-Cre<sup>+/-</sup>-FoxP3-CreYFP-*Ramp1*<sup>flox/flox</sup> mice. Mice were bred and maintained in the animal facility at Harvard Medical School (HMS) under specific pathogen-free (SPF) conditions with food and water *ad libitum* and a 12 h dark/light cycle. All experiments with animals were

approved by the Harvard Medical School Institutional Animal Use and Care Committee (protocols IS00001257 and IS00000054-6).

### **Systemic and targeted viral DREADD expression and chemogenetic activation**

For systemic AAV-mediated delivery, we utilized the adeno-associated virus AAV.PhP.S-hSyn-DIO-hM3D(Gq)-mCherry (AAV<sup>hM3Dq</sup>) to mediate Cre-dependent expression of the designer receptor exclusively activated by designer drugs (DREADD) hM3Dq in neurons (24). Viruses were produced at the Boston Children's Hospital (BCH) viral core facility. Neonatal pups (either Cre<sup>+</sup> or Cre<sup>-</sup> littermates) at postnatal stage 1 (P1) were injected intraperitoneally with 10 $\mu$ L of AAV<sup>hM3Dq</sup> at a dose of  $2 \times 10^{11}$  vg per mouse.

For DRG-targeted AAV-mediated delivery, we utilized the AAV9-hSyn-DIO-hM3D(Gq)-mCherry (AAV9<sup>hM3Dq</sup>). Viruses were purchased from Addgene. 10  $\mu$ L of AAV9<sup>hM3Dq</sup> virus was injected intrathecally on three consecutive days. Mice were briefly anesthetized with isoflurane and injected in the L5-L6 region. Mice were rested for 3-4 weeks before being used for experiments.

For vagal ganglia-targeted expression, the nodose/jugular ganglia were bilaterally injected as previously described (61). Briefly, adult mice were anesthetized and an incision was made along the ventral surface of the neck. The nodose/jugular ganglia were surgically exposed by blunt dissection and a micropipette containing the virus was inserted into the nodose ganglia. 150 nL of AAV9<sup>hM3Dq</sup> virus was injected using a Nanoinject II injector (Drummond). Mice were allowed to recover for 4 weeks before being used for experiments.

To stimulate neuronal activation in mice, 1mg/kg of clozapine-N-oxide (CNO, Tocris 4936) was injected intraperitoneally. Mice were administered CNO every other day for a 2-week period, or consecutively for 1 day or 7 days. Mice were sacrificed the day after the last CNO injection, unless otherwise specified in the Results section.

### **Trpv1+ DRG neuron ablation**

For targeted ablation of Trpv1+ DRG neurons, 4-6 week old mice were intrathecally injected with Resiniferatoxin (RTX, Alamone labs R-400), (25 ng/mouse) or vehicle in 10 $\mu$ L of 0.25% DMSO/0.02% Tween-80/0.05% ascorbic acid/PBS in the L5-L6 region under isoflurane on two consecutive days as described (62, 109). Control mice were injected intrathecally with vehicle alone. Mice were allowed to rest for 3-4 weeks before being used for experiments. We confirmed the loss of Trpv1+ neurons in the DRG but not vagal ganglia by immunostaining (see section below) or reduced thermal responses to noxious heat during hot plate tests (55°C).

### **RAMP1 antagonist administration**

For antagonist experiments, BIBN 4096 (Tocris, 4561) was injected intraperitoneally at the dose of 0.3mg/kg 1 hour before CNO injections.

## DSS induced colitis and *Citrobacter rodentium* infection

For DSS-induced colitis in mice, 2.5% dextran sulfate sodium salt (DSS, Thermo Scientific) was dissolved in the drinking water and given to mice for 6 days, followed by normal drinking water for 4 days. Mice were monitored daily for morbidity (piloerection, lethargy), weight loss and rectal bleeding.

For *Citrobacter rodentium* infections in mice, *C. rodentium* strain DBS100 (ATCC, 51459) was used. Bacteria were grown overnight for 16-18 hours in Luria Bertani (LB) broth at 37°C at 250 rpm. The OD<sub>600</sub> was determined to estimate bacterial density and serial plating was performed to quantify the infection dose by counting colony forming units (CFU). Mice were fasted overnight and then orally gavaged with 200µL of sterile PBS containing 2 x 10<sup>9</sup> CFU. Mice were monitored daily throughout the experiment. To detect *C. rodentium* colonization, fecal pellets, liver, or spleen were homogenized in 1 mL of PBS, serially diluted, and plated on MacConkey agar for counting. *C. rodentium* CFU were counted after overnight incubation at 37°C.

## Photo-conversion procedures

Colon was photoconverted as previously described (55). Briefly, a custom-built fiberoptic endoscope (ZIBRA Corporation) was coupled to a handheld 405 nm blue purple laser (5mW) via an in-house custom-made connection device (fixed mounts from ThorLabs). Mice were anesthetized with ketamine:xylazine (10 mg/kg:2mg/kg i.p). After cleansing the colon of fecal pellets with PBS, the fiberoptic endoscope was inserted through the anus to a depth of 3 cm. The laser was switched on, exposing the inner colon to violet light (3.5 mm beam diameter). Subsequently, the endoscope was gently retracted, pausing at 2 mm increments for 30 second light pulses at each interval (for a total of up to 10 minutes).

## Immunocyte isolation from tissues

**Spleen:** Single-cell suspensions were prepared by mashing the splenic tissue through a 70µm cell strainer followed by washing in RPMI containing 5% fetal calf serum (FCS). Red blood cells in the spleen were lysed with ACK lysing buffer (Gibco, ref A10492-01).

**Mesenteric lymph node (mLN)**—mLNs were minced into small pieces and dissociated in collagenase solution (1 mg/mL collagenase VIII (Sigma), 0.1mg/mL DNase I (Sigma) and 2% FCS in RPMI) with constant shaking at 37°C for 30 minutes. Single-cell suspensions were filtered through a 40µm cell strainer and washed with RPMI containing 5% FCS.

**Ileum, Cecum, Colon:** Intestines were cleaned (Peyer's patches were removed in the case of the ileum), and treated with RPMI containing 1 mM DTT, 20 mM EDTA and 2% FCS at 37°C for 15 minutes to remove epithelial cells. Tissues were then minced and dissociated in collagenase solution (1.5 mg/mL collagenase II (Gibco), 0.5mg/mL dispase (Gibco) and 1% FCS in RPMI) with constant stirring at 37°C for 40 minutes. Single-cell suspensions were filtered through a 40µm cell strainer and washed with RPMI containing 5% FCS.

## Flow cytometry

Single-cell suspensions from spleen and intestinal tissues were prepared as above.

The cells were stained with 2 constant panels of antibodies for consistency. The first panel (lymphoid panel) included surface markers for CD19, CD4, CD8a, CD8b, TCR- $\beta$ , TCR- $\gamma\delta$ , NK1.1, CD138, CD44, and intracellular markers for ROR $\gamma$ , FoxP3, Tbet, Gata3, Helios. The second panel (myeloid panel) included surface markers for CD45, CD19, CD11b, CD11c, Ly6c, Ly6g, PDCA-1, F4/80, CD103, and MHCII. The Thetis/Janus cell staining panel included surface markers for CD45, TCR- $\beta$ , TCR- $\gamma\delta$ , B220, CD11c, CD127, MHCII, CCR6, CXCR6, and intracellular markers for ROR $\gamma$ , FoxP3. The cells were stained with zombie live/dead dye (BioLegend) at 4°C for 20 minutes, followed by surface staining at 4°C for 30 minutes. For intracellular staining, cells were fixed in eBioscience Fix/Perm buffer at room temperature for 1 hour, followed by permeabilization in eBioscience permeabilization buffer at room temperature for 1 hour in the presence of antibodies. For Annexin-V staining, the cells were stained with antibody for Annexin-V in Annexin-V binding buffer at room temperature for 10 minutes after surface staining. Cells were acquired with a Symphony flow cytometer (BD Biosciences) and analysis was performed with FlowJo (Tree Star) software.

## Whole mount staining

Mice were euthanized and a small piece (3 mm x3 mm) of distal colon was collected for staining. The colons were opened and fixed in a Silgard dish with 4% PFA at 4°C for 2 hours. Then the tissues were washed with PBST (PBS with 0.5% Triton-X100) 6 times at room temperature for 20 minutes, followed by incubation with primary antibodies (Tuj1 and mCherry, or CGRP and FoxP3) in blocking buffer (20% DMSO, 5% donkey serum or goat serum in PBST) for 2-3 days and corresponding secondary antibodies in blocking buffer for 1-2 days. In subsets of experiments, tissue was dehydrated with serial (50%, 80%, 100%) methanol solution and cleared in BABB buffer (1 volume Benzyl Alcohol to 2 volume Benzyl Benzoate). The tissues were mounted on glass slides using vacuum grease for imaging. Three different fields of each tissue were imaged by Ti2 Spinning Disk microscope (Nikon) or a Stellaris 8 FALCON CFS system (Leica) and processed by ImageJ software. All images were maximum intensity projections of z-stacks. For quantification of the myenteric plexus in whole mount colon images, the percentage of mCherry+ area out of total Tuj1+ area was determined for each sample as an average of 2 fields per mouse and quantified by investigators blinded to genotypes.

## Immunofluorescence and Microscopy

For immunostaining of extrinsic ganglia, tissues were placed in 4% PFA for 1-2 hours. Thoracic (T11-T13) DRG, lumbar DRG (L5-L6), and vagal ganglia were dissected, incubated overnight at 4°C in 30% sucrose, and embedded in OCT. Sections (14  $\mu$ m) were cut, blocked with 10% NDS, 0.05% Tween-20 in PBS for 2 hours at room temperature, and stained with primary antibodies (goat anti-mCherry, rabbit anti-Tuj1) overnight at room temperature. Sections were washed in PBS, then stained with secondary antibodies (donkey anti-goat Alexa594, donkey anti-rabbit Alexa488) for 2 hours at room temperature. After washing with PBS, sections were mounted in VectaShield (Vector Labs). Sections were



imaged on a Leica Stellaris 8 FALCON CFS confocal microscope at 20X magnification. Leica software (Leica Application Suite X) was used for image capture and post-processing. For quantification of extrinsic ganglia neurons, the percentage of mCherry+ neurons out of the total Tuj1+ neurons were determined for each sample as an average of 3-5 fields per mouse and quantified by investigators were blinded to genotypes.

### Gut histopathology

Mice were euthanized and colon tissues were collected and fixed in 10% formalin for at least 24 hours prior to H&E (hematoxylin and eosin) staining. Whole cross-sections were scanned and imaged on a widefield microscope (Nikon) at either 10X or 20X magnitude. For H&E staining, images were analyzed using a scoring system as previously described (110). Briefly, cross-sections were randomly split into 8 sections and 4 random sections were scored qualitatively using a 0-5 point scale for immune infiltrate, goblet cell loss, crypt density, crypt hyperplasia, muscle thickening, submucosal infiltrate, ulceration, and abscess. Scores from each item were combined for a composite score for each mouse. Scores from each section were averaged for each mouse. Scoring was performed blinded.

### Fecal DNA extraction, 16S rDNA sequencing, and data analysis

Feces from colons were collected and frozen at  $-80^{\circ}\text{C}$  until use. Bacterial genomic DNA from fecal samples was extracted using phenol:chloroform:isoamyl alcohol and purified with the QIAquick PCR Purification kit (Qiagen). Purified DNA was quantified by Qubit dsDNA HS Assay (Thermo Fisher) and normalized to  $6\text{ng}/\mu\text{l}$  for following amplification. Amplicons were quantified by Qubit dsDNA HS Assay and combined with equal mass to make a pooled library. The pooled library was purified and multiplexed sequenced (Illumina MiSeq, 251 nt x 2 pair-end reads with 12 nt index reads) through Harvard's Biopolymers Facility. Raw sequencing data was processed with QIIME2. In brief, raw sequencing data was imported to QIIME2 and demultiplexed, then DADA2 was used for sequence quality control and feature table construction. The feature table was used for beta diversity analysis, taxonomic analysis, and differential abundance testing using QIIME2. Beta group significance was determined by permutational analysis of variance (PERMANOVA). Identification of taxa associated with different groups was determined using Analysis of Composition of Microbiomes (ANCOM).

### Single-Cell RNA sequencing and data analysis

**Sample preparation and sequencing:** Single-cell RNA sequencing (scRNAseq) experiments were performed and analyzed as previously described (111) Cecum cell suspensions were stained with surface markers for CD45, CD4, CD19, CD8a, CD11b, CD11c, TCR- $\gamma\delta$ , NK1.1 and DAPI as a viability dye, along with hashtag antibodies (hashtag 1, CTRL#1; hashtag 3, CTRL#2; hashtag 7, Trpv1-ADC#1; hashtag 9, Trpv1-ADC#2). Cells were sorted as DAPI-CD45+. Additional sorting was performed for CD19 $^{-}$ CD45 $^{+}$ , NK1.1 $^{+}$ CD45 $^{+}$ , and TCR- $\gamma\delta$  $^{+}$ CD45 $^{+}$  to enrich for these populations. All samples were pooled together, centrifuged, and resuspended in 0.04% BSA. Encapsulation was done on the 10X Chromium microfluidic instrument (10X Genomics). Libraries were prepared using Chromium Single cell 3' reagents kit v2 according to manufacturer's

protocol. Hashtag oligonucleotide (HTO) libraries were prepared as described in (112). Libraries were sequenced together on the Illumina HiSeq X.

**Data analysis:** scRNAseq data were processed using the standard CellRanger pipeline (10X Genomics). HTO counts were obtained using the CITE-seq-Count package (113). Data was analysed in R using the Seurat package (114). HTOs were assigned to cells using the HTODemux function, and doublets were eliminated from analysis. Cells with less than 700 UMIs or 500 genes and more than 2,500 UMIs, 10,000 genes and 5% of reads mapped to mitochondrial genes were also excluded from the analysis. Dimensionality reduction, visualization and clustering analysis were performed in Seurat using the NormalizeData, ScaleData, FindVariableGenes, RunPCA, FindNeighbours (dims=1:30), RunUMAP (dims=1:30) and FindClusters functions. Cluster identity was determined based on expression of key marker genes (Fig. S7A). The SubsetData function was used to gate individual clusters for further analysis.

Differentially expressed genes (DEGs) between Trpv1-ADC and CTRL mice were obtained using the FindMarkers function with the cutoff based on fold change and P value (logfc.threshold = 0.5 and adjusted P value < 0.05) on 7 populations including CD4<sup>+</sup> Tconv cells (T4conv), CD4<sup>+</sup> Treg cells (Treg), CD8a<sup>+</sup>CD8b<sup>+</sup> T cells (T8ab), CD160<sup>+</sup> IEL (IEL-like), B cells (B), ILCs (ILC), and selected myeloid cells (Macrophage and dendritic cells, MacDC), respectively. Then the DEGs from each population were collated non-redundantly. The average expression of these DEGs in each sample (2 pairs of Trpv1-ADC and CTRL mice) across each population were generated using AverageExpression function. Heatmaps of differentially expressed genes were generated using Morpheus (<https://software.broadinstitute.org/morpheus>).

**Gene signatures:** The IEL gene signature was based on the expression of the following marker genes: *Klra1*, *Klre1*, *Klra7*, *Itgae*, *Cd160*, *Klrk1*, *Fas1*, *Itgb7*, *Ccr9*, *Cd8a*. The Helios Treg gene signature was on the expression of the following marker genes: *Cd200r1*, *Cd83*, *Dgat2*, *Epas1*, *Fam46a*, *Gas2l3*, *Ikzf2*, *Il9r*, *Naip5*, *Nrp1*, *Ppp2r3a*, *Swap70*, *Foxp3*. The Rorc Treg gene signature was on the expression of the following marker genes: *Ccr1*, *Ccr2*, *Ccr5*, *Ccr9*, *Clic4*, *F2rl2*, *Gpr15*, *Havcr2*, *Itgb5*, *Marcks*, *Matn2*, *Nr1d1*, *Prg4*, *Rorc*.

### Data analysis and statistics

Data are represented as mean and standard deviation where n represents the number of mice, unless indicated otherwise. Statistical tests used were unpaired Student's t test with Holm-Sidak correction for multiple comparison, or Two-way repeated measures ANOVA as indicated in the figure legends. Differences were considered significant if  $p < 0.05$ . Statistics were performed in GraphPad Prism.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements:

We thank Drs. Dan Littman, Viviana Gradinaru, Meng Wu, Meena Rao, and members of Chiu and Mathis/Benoist lab for insightful discussion and advice, L. Yang and D. Mallah for help with computational analyses, K. Hattori and S. Choi for help with mice, Dr H. Basu for help with image analysis, Dr P. Montero-Llopis and MicRoN facility for microscopy, the Boston Children's Hospital Viral Core for virus stocks, and Ian Magill for single-cell sequencing.

## Funding:

This work was supported by National Institutes of Health (NIH) grants AI125603 and AI150686 and the JPB Foundation to CB&DM; RO1DK127257, Kenneth Rainin Foundation, and the Food Allergy Science Initiative to IMC. KAM was supported by NIH fellowship F32DK137456, SG-P by a fellowship from European Molecular Biology Organisation (ALTF 547-2019).

## References and Notes

- Jacobson A, Yang D, Vella M, Chiu IM, The intestinal neuro-immune axis: crosstalk between neurons, immune cells, and microbes. *Mucosal. Immunol* 14, 555–565 (2021). [PubMed: 33542493]
- Wang H, Foong JPP, Harris NL, Bornstein JC, Enteric neuroimmune interactions coordinate intestinal responses in health and disease. *Mucosal. Immunol* 15, 27–39 (2022). [PubMed: 34471248]
- Cryan JF, Dinan TG, Gut microbiota: Microbiota and neuroimmune signalling-Metchnikoff to microglia. *Nat Rev Gastroenterol. Hepatol* 12, 494–496 (2015). [PubMed: 26215386]
- Blackshaw LA, Brookes SJ, Grundy D, Schemann M, Sensory transmission in the gastrointestinal tract. *Neurogastroenterol. Motil* 19, 1–19 (2007).
- Costa M, Brookes SJ, Hennig GW, Anatomy and physiology of the enteric nervous system. *Gut*. 47 Suppl 4, iv15–iv19 (2000). [PubMed: 11076898]
- McCorry LK, Physiology of the autonomic nervous system. *Am. J Pharm. Educ* 71, 78 (2007). [PubMed: 17786266]
- Zeisel A et al. , Molecular architecture of the mouse nervous system. *Cell*. 174, 999–1014 (2018). [PubMed: 30096314]
- Hockley JRF et al. , Single-cell RNAseq reveals seven classes of colonic sensory neuron. *Gut*. 68, 633–644 (2019). [PubMed: 29483303]
- Kupari J et al. , An Atlas of Vagal Sensory Neurons and Their Molecular Specialization. *Cell Rep*. 27, 2508–2523 (2019). [PubMed: 31116992]
- Talbot J et al. , Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier. *Nature*. 579, 575–580 (2020). [PubMed: 32050257]
- Seillet C et al. , The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity. *Nat Immunol*. 21, 168–177 (2020). [PubMed: 31873294]
- Pascal M et al. , The neuropeptide VIP potentiates intestinal innate type 2 and type 3 immunity in response to feeding. *Mucosal. Immunol* 15, 629–641 (2022). [PubMed: 35501356]
- Wallrapp A et al. , The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation. *Nature*. 549, 351–356 (2017). [PubMed: 28902842]
- Cardoso V et al. , Neuronal regulation of type 2 innate lymphoid cells via neuromedin U. *Nature*. 549, 277–281 (2017). [PubMed: 28869974]
- Klose CSNet al. , The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. *Nature*. 549, 282–286 (2017). [PubMed: 28869965]
- Gabanyi I et al. , Neuro-immune interactions drive tissue programming in intestinal macrophages. *Cell*. 164, 378–391 (2016). [PubMed: 26777404]
- Matheis F et al. , Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss. *Cell*. 180, 64–78 (2020). [PubMed: 31923400]
- Moriyama S et al. ,  $\beta$ 2-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses. *Science*. 359, 1056–1061 (2018). [PubMed: 29496881]

19. Urban DJ, Roth BL, DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. *Annu Rev Pharmacol. Toxicol* 55, 399–417 (2015). [PubMed: 25292433]
20. Roth BL, DREADDs for Neuroscientists. *Neuron*. 89, 683–694 (2016). [PubMed: 26889809]
21. Krashes MJ et al. , Rapid, reversible activation of AgRP neurons drives feeding behavior in mice. *J Clin Invest*. 121, 1424–1428 (2011). [PubMed: 21364278]
22. Atasoy D, Betley JN, Su HH, Sternson SM, Deconstruction of a neural circuit for hunger. *Nature*. 488, 172–177 (2012). [PubMed: 22801496]
23. Yoo ES et al. ,  $\text{GABA}_{\text{A}}$ -coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents. *Cell Rep*. 37, 109997 (2021). [PubMed: 34788630]
24. Chan KY et al. , Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nat Neurosci*. 20, 1172–1179 (2017). [PubMed: 28671695]
25. Armbruster BN et al. , Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl Acad Sci U S A*. 104, 5163–5168 (2007). [PubMed: 17360345]
26. Ogura T et al. , Utility of intraperitoneal administration as a route of AAV serotype 5 vector-mediated neonatal gene transfer. *J Gene Med*. 8, 990–997 (2006). [PubMed: 16685745]
27. Foust KD et al. , Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. *Hum. Gene Ther* 19, 61–70 (2008). [PubMed: 18052722]
28. Machida A et al. , Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice. *Mol. Pain* 9, 36 (2013). [PubMed: 23866078]
29. Phillips RJ, Powley TL, Innervation of the gastrointestinal tract: patterns of aging. *Auton. Neurosci* 136, 1–19 (2007). [PubMed: 17537681]
30. Uesaka T, Young HM, Pachnis V, Enomoto H, Development of the intrinsic and extrinsic innervation of the gut. *Dev. Biol* 417, 158–167 (2016). [PubMed: 27112528]
31. Woo SH et al. , Piezo2 is required for Merkel-cell mechanotransduction. *Nature*. 509, 622–626 (2014). [PubMed: 24717433]
32. Harris JA et al. , Anatomical characterization of Cre driver mice for neural circuit mapping and manipulation. *Front Neural Circuits*. 8, 76 (2014). [PubMed: 25071457]
33. Olson W et al. , Sparse genetic tracing reveals regionally specific functional organization of mammalian nociceptors. *eLife*. 6, (2017).
34. Savitt JM et al. , Bcl-x is required for proper development of the mouse substantia nigra. *J Neurosci*. 25, 6721–6728 (2005). [PubMed: 16033881]
35. Cavanaugh DJ et al. , Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. *J Neurosci*. 31, 5067–5077 (2011). [PubMed: 21451044]
36. Rossi J et al. , Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. *Cell Metab*. 13, 195–204 (2011). [PubMed: 21284986]
37. Leshan RL et al. , Leptin action through hypothalamic nitric oxide synthase-1-expressing neurons controls energy balance. *Nat Med*. 18, 820–823 (2012). [PubMed: 22522563]
38. Taniguchi H et al. , A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. *Neuron*. 71, 995–1013 (2011). [PubMed: 21943598]
39. Gershon MD, Margolis KG, The gut, its microbiome, and the brain: connections and communications. *J. Clin. Invest* 131, (2021).
40. Cryan JF et al. , The Microbiota-Gut-Brain Axis. *Physiol Rev*. 99, 1877–2013 (2019). [PubMed: 31460832]
41. Yang D et al. , Nociceptor neurons direct goblet cells via a CGRP-RAMP1 axis to drive mucus production and gut barrier protection. *Cell*. 185, 4190–4205 (2022). [PubMed: 36243004]
42. Zhang W et al. , Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection. *Cell*. 185, 4170–4189 (2022). [PubMed: 36240781]

43. Caterina MJ et al. , The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature*. 389, 816–824 (1997). [PubMed: 9349813]
44. Ramanan D et al. , Regulatory T cells in the face of the intestinal microbiota. *Nat Rev Immunol*. In press, (2023).
45. Traxinger BR, Richert-Spuhler LE, Lund JM, Mucosal tissue regulatory T cells are integral in balancing immunity and tolerance at portals of antigen entry. *Mucosal. Immunol* 15, 398–407 (2022). [PubMed: 34845322]
46. Yissachar N et al. , An intestinal organ culture system uncovers a role for the nervous system in microbe-immune crosstalk. *Cell*. 168, 1135–1148 (2017). [PubMed: 28262351]
47. Yan Y et al. , Interleukin-6 produced by enteric neurons regulates the number and phenotype of microbe-responsive regulatory T cells in the gut. *Immunity*. 54, 499–513 (2021). [PubMed: 33691135]
48. Teratani T et al. , The liver-brain-gut neural arc maintains the Treg cell niche in the gut. *Nature*. 585, 591–596 (2020). [PubMed: 32526765]
49. Galván-Peña S et al. , A dynamic atlas of immunocyte migration from the gut. *bioRxiv*. 10.1101/2022.11.16.516757 (2022).
50. Hanna BS et al. , The gut microbiota promotes distal tissue regeneration via ROR $\gamma^+$  regulatory T cell emissaries. *Immunity*. 56, 829–846 (2023). [PubMed: 36822206]
51. Chowdhary K et al. , An interwoven network of transcription factors, with divergent influences from FoxP3, underlies Treg diversity. *bioRxiv*. DOI 10.1101/2023.05.18.541358 (2023).
52. Kedmi R et al. , A ROR $\gamma^+$  cell instructs gut microbiota-specific Treg cell differentiation. *Nature*. 610, 737–743 (2022). [PubMed: 36071167]
53. Akagbosu B et al. , Novel antigen presenting cell imparts Treg-dependent tolerance to gut microbiota. *Nature*. 610, 752–760 (2022). [PubMed: 36070798]
54. Tomura M et al. , Monitoring cellular movement in vivo with photoconvertible fluorescence protein "Kaede" transgenic mice. *Proc Natl Acad Sci U S A*. 105, 10871–10876 (2008). [PubMed: 18663225]
55. Morton AM et al. , Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. *Proc Natl Acad Sci U S A*. 111, 6696–6701 (2014). [PubMed: 24753589]
56. Miller I et al. , Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. *Cell Rep*. 24, 1105–1112 (2018). [PubMed: 30067968]
57. Crepin VF, Collins JW, Habibzay M, Frankel G, Citrobacter rodentium mouse model of bacterial infection. *Nat Protoc*. 11, 1851–1876 (2016). [PubMed: 27606775]
58. van den Brink SC et al. , Single-cell sequencing reveals dissociation-induced gene expression in tissue subpopulations. *Nat. Methods* 14, 935–936 (2017). [PubMed: 28960196]
59. Ramanan D et al. , Homeostatic, repertoire and transcriptional relationships between colon T regulatory cell subsets. *bioRxiv*. DOI 10.1101/2023.05.17.541199 (2023).
60. Skorput AGJ et al. , Targeting the somatosensory system with AAV9 and AAV2retro viral vectors. *PLoS One*. 17, e0264938 (2022). [PubMed: 35271639]
61. Chang RB et al. , Vagal Sensory Neuron Subtypes that Differentially Control Breathing. *Cell*. 161, 622–633 (2015). [PubMed: 25892222]
62. Mishra SK, Hoon MA, Ablation of TrpV1 neurons reveals their selective role in thermal pain sensation. *Mol. Cell Neurosci* 43, 157–163 (2010). [PubMed: 19853036]
63. Price TJ, Flores CM, Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. *J Pain*. 8, 263–272 (2007). [PubMed: 17113352]
64. Chiu IM, Von Hehn CA, Woolf CJ, Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. *Nat Neurosci*. 15, 1063–1067 (2012). [PubMed: 22837035]
65. Cao YQ et al. , Primary afferent tachykinins are required to experience moderate to intense pain. *Nature*. 392, 390–394 (1998). [PubMed: 9537322]
66. Russell FA et al. , Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol Rev*. 94, 1099–1142 (2014). [PubMed: 25287861]

67. Assas BM, Pennock JI, Miyan JA, Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. *Front Neurosci.* 8, 23 (2014). [PubMed: 24592205]
68. Baral P, Udit S, Chiu IM, Pain and immunity: implications for host defence. *Nat Rev Immunol.* 19, 433–447 (2019). [PubMed: 30874629]
69. Nagashima H et al. , Neuropeptide CGRP limits group 2 innate lymphoid cell responses and constrains type 2 inflammation. *Immunity.* 51, 682–695 (2019). [PubMed: 31353223]
70. Wallrapp A et al. , Calcitonin gene-related peptide negatively regulates alarmin-driven type 2 innate lymphoid cell responses. *Immunity.* 51, 709–723 (2019). [PubMed: 31604686]
71. Xu H et al. , Transcriptional atlas of intestinal immune cells reveals that neuropeptide  $\alpha$ -CGRP modulates group 2 innate lymphoid cell responses. *Immunity.* 51, 696–708 (2019). [PubMed: 31618654]
72. Pinho-Ribeiro FA et al. , Blocking neuronal signaling to immune cells treats streptococcal invasive infection. *Cell.* 173, 1083–1097 (2018). [PubMed: 29754819]
73. Baral P et al. , Nociceptor sensory neurons suppress neutrophil and gammadelta T cell responses in bacterial lung infections and lethal pneumonia. *Nat Med.* 24, 417–426 (2018). [PubMed: 29505031]
74. Hanc P et al. , Multimodal control of dendritic cell functions by nociceptors. *Science.* 379, eabm5658 (2023). [PubMed: 36996219]
75. Wang K et al. , Neuronal, stromal, and T-regulatory cell crosstalk in murine skeletal muscle. *Proc. Natl. Acad. Sci. U. S. A.* 117, 5402–5408 (2020). [PubMed: 32102913]
76. Miller PS et al. , Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. *Biochem. Biophys. Res. Commun* 391, 437–442 (2010). [PubMed: 19914210]
77. Veiga-Fernandes H, Mucida D, Neuro-immune interactions at barrier surfaces. *Cell.* 165, 801–811 (2016). [PubMed: 27153494]
78. Klose CS, Artis D, Neuronal regulation of innate lymphoid cells. *Curr. Opin. Immunol* 56, 94–99 (2019). [PubMed: 30530300]
79. Muller PA, Matheis F, Mucida D, Gut macrophages: key players in intestinal immunity and tissue physiology. *Curr. Opin. Immunol* 62, 54–61 (2020). [PubMed: 31841704]
80. Vanuytsel T, Bercik P, Boeckxstaens G, Understanding neuroimmune interactions in disorders of gut-brain interaction: from functional to immune-mediated disorders. *Gut.* 72, 787–798 (2023). [PubMed: 36657961]
81. Klein Wolterink RGJ, Wu GS, Chiu IM, Veiga-Fernandes H, Neuroimmune Interactions in Peripheral Organs. *Annu. Rev. Neurosci* 45, 339–360 (2022). [PubMed: 35363534]
82. Matteoli G et al. , A distinct vagal anti-inflammatory pathway modulates intestinal muscularis resident macrophages independent of the spleen. *Gut.* 63, 938–948 (2014). [PubMed: 23929694]
83. Muller PA et al. , Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. *Cell.* 158, 300–313 (2014). [PubMed: 25036630]
84. Dalli J, Colas RA, Arnardottir H, Serhan CN, Vagal Regulation of Group 3 Innate Lymphoid Cells and the Immunosolvent PCTRI Controls Infection Resolution. *Immunity.* 46, 92–105 (2017). [PubMed: 28065837]
85. Yu HB et al. , Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. *Proc Natl Acad Sci U S A.* 118, (2021).
86. Viola MF et al. , Dedicated macrophages organize and maintain the enteric nervous system. *Nature.* 618, 818–826 (2023). [PubMed: 37316669]
87. Kuner R, Kuner T, Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain. *Physiol Rev.* 101, 213–258 (2021). [PubMed: 32525759]
88. Kay MW, Jain V, Panjrath G, Mendelowitz D, Targeting Parasympathetic Activity to Improve Autonomic Tone and Clinical Outcomes. *Physiology. (Bethesda.)* 37, 39–45 (2022). [PubMed: 34486396]

89. Singh R, Zogg H, Ghoshal UC, Ro S, Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders. *Front Pharmacol.* 13, 808195 (2022). [PubMed: 35145413]
90. Bódi N, Szalai Z, Bagyanszki M, Nitrergic Enteric Neurons in Health and Disease-Focus on Animal Models. *Int. J. Mol. Sci.* 20, (2019).
91. Tracey KJ, The inflammatory reflex. *Nature.* 420, 853–859 (2002). [PubMed: 12490958]
92. Kelly MJ, Breathnach C, Tracey KJ, Donnelly SC, Manipulation of the inflammatory reflex as a therapeutic strategy. *Cell Rep Med.* 3, 100696 (2022). [PubMed: 35858588]
93. Zhang S et al. , Nonpeptidergic neurons suppress mast cells via glutamate to maintain skin homeostasis. *Cell.* 184, 2151–2166 (2021). [PubMed: 33765440]
94. Riol-Blanco L et al. , Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. *Nature.* 510, 157–161 (2014). [PubMed: 24759321]
95. Cohen JA et al. , Cutaneous TRPV1<sup>+</sup> neurons trigger protective innate type 17 anticipatory immunity. *Cell.* 178, 919–932 (2019). [PubMed: 31353219]
96. Enamorado M et al. , Immunity to the microbiota promotes sensory neuron regeneration. *Cell.* 186, 607–620 (2023). [PubMed: 36640762]
97. Krukowski K et al. , CD8<sup>+</sup> T cells and endogenous IL-10 are required for resolution of chemotherapy-induced neuropathic pain. *J Neurosci.* 36, 11074–11083 (2016). [PubMed: 27798187]
98. Laumet G et al. , Cisplatin educates CD8<sup>+</sup> T cells to prevent and resolve chemotherapy-induced peripheral neuropathy in mice. *Pain.* 160, 1459–1468 (2019). [PubMed: 30720585]
99. Basso L et al. , Endogenous analgesia mediated by CD4<sup>+</sup> T lymphocytes is dependent on enkephalins in mice. *J Neuroinflammation.* 13, 132 (2016). [PubMed: 27245576]
100. Boué J et al. , Endogenous regulation of visceral pain via production of opioids by colitogenic CD4(+) T cells in mice. *Gastroenterology.* 146, 166–175 (2014). [PubMed: 24055279]
101. Austin PJ, Kim CF, Perera CJ, Moalem-Taylor G, Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. *Pain.* 153, 1916–1931 (2012). [PubMed: 22789131]
102. Lees JG, Duffy SS, Perera CJ, Moalem-Taylor G, Depletion of Foxp3<sup>+</sup> regulatory T cells increases severity of mechanical allodynia and significantly alters systemic cytokine levels following peripheral nerve injury. *Cytokine.* 71, 207–214 (2015). [PubMed: 25461400]
103. Liu XJ et al. , Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. *Cell Res.* 24, 1374–1377 (2014). [PubMed: 25112711]
104. Duffy SS et al. , Regulatory T cells and their derived cytokine, Interleukin-35, reduce pain in experimental autoimmune encephalomyelitis. *J Neurosci.* 39, 2326–2346 (2019). [PubMed: 30651334]
105. Koren T et al. , Insular cortex neurons encode and retrieve specific immune responses. *Cell.* 184, 5902–5915 (2021). [PubMed: 34752731]
106. Florsheim EB et al. , Immune sensing of food allergens promotes avoidance behaviour. *Nature.* (2023).
107. Plum T et al. , Mast cells link immune sensing to antigen-avoidance behaviour. *Nature.* (2023).
108. Oh-hashi Y et al. , Elevated sympathetic nervous activity in mice deficient in alphaCGRP. *Circ. Res.* 89, 983–990 (2001). [PubMed: 11717154]
109. Guptill V et al. , Disruption of the transient receptor potential vanilloid 1 can affect survival, bacterial clearance, and cytokine gene expression during murine sepsis. *Anesthesiology.* 114, 1190–1199 (2011). [PubMed: 21383614]
110. Asseman C et al. , An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. *J Exp Med.* 190, 995–1004 (1999). [PubMed: 10510089]
111. Kiner E et al. , Gut CD4<sup>+</sup> T cell phenotypes are a continuum molded by microbes, not by T<sub>H</sub> archetypes. *Nat. Immunol.* (2021).
112. Stoeckius M et al. , Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. *Genome Biol.* 19, 224 (2018). [PubMed: 30567574]

113. Stoeckius M et al. , Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods*. 14, 865–868 (2017). [PubMed: 28759029]
114. Butler A et al. , Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol*. 36, 411–420 (2018). [PubMed: 29608179]


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript






**Fig 1. Screening neuronal subtypes for immunomodulatory capabilities using viral mediated DREADDs.**

(A) Schematic of experimental procedures describing setup of DREADD-based chemogenetic screen for neuronal effects on the gut immune system.


(B) Diagram showing neuronal subtypes in different anatomical locations (dorsal root ganglia, nodose ganglia, enteric nervous system) that innervate the gut and markers expressed in each location.

(C) Representative images of mCherry (red) and Tuj1 ( $\beta$ III-tubulin, gray) staining in nodose ganglia (NG) and dorsal root ganglia (DRG) and myenteric plexus (MP) of the ENS after AAV.PhP.S-hSyn-DIO-mCherry-DREADD labeling of eight Cre lines. Scale bars are 100 $\mu$ m.

(D) Quantification of mCherry expression patterns across the eight Cre lines in the DRG, NG, and MP. For DRG and NG, the proportion of mCherry<sup>+</sup> cells out of total Tuj1<sup>+</sup> cells were quantified (4-5 fields per mouse). For MP, the area labeled by mCherry out of total Tuj1 area was quantified (2 fields per mouse). Gray bars indicate the expected expression range for marker genes.



**Fig 2. Distinct gut immune changes after DREADD-mediated neuronal activation.** (A-F) Quantification of proportions of ileum RORγ<sup>+</sup> Tconv (A), ileum neutrophil (B), ileum MHCII<sup>+</sup> MNP (C), colon ILC2 (D), colon RORγ<sup>+</sup> Treg (E), and cecum RORγ<sup>+</sup> Treg (F) with representative flow cytometric plots after chemogenetic activation of different neuronal subsets in distinct ADC mice and controls (CTRL). (G) Heatmap of average fold changes (relative to CTRL) for significantly changed immune cell populations in the ileum, cecum, and colon from each Cre line compared to control littermates after CNO treatment (P<0.05). White squares are where P>0.05. Each symbol (A-F) represents an individual mouse; Error bars represent mean and standard deviation. \*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001 (unpaired Student's t test with Holm-Sidak correction for multiple comparison). Data are representative of 2 independent experiments. n = 7-12 mice/group.



**Fig 3. Microbiome changes upon specific neuronal activation.**


(A) Alpha diversity rarefaction plots of microbial populations in different pairs of ADC mice and CTRL mice after CNO treatment.

(B) Principal coordinates analysis (PCoA) of unweighted UniFrac distance measurements in different ADC mice and CTRL mice after CNO treatment.

(C) Phylum-level analysis of the microbiome in the colon of Trpv1-ADC and CTRL mice.

(D) Quantification of proportions of Bacteroidetes (phylum-level) in the colon of different ADC mice and CTRL mice after CNO treatment.

Each symbol (C and E) represents an individual mouse; Error bars represent mean and standard deviation. \*,  $P < 0.05$  (unpaired Student's *t* test with Holm-Sidak correction for multiple comparison). Data are representative of 2 independent experiments.  $n = 7-12$  mice/group.



**Fig 4. Trpv1+ neurons control the gut Treg cell niche.**

(A) Representative flow cytometric plots and quantification of proportions of RORγ<sup>+</sup> Tregs in the spleen, mLN, ileum and colon tissues from Trpv1-ADC and CTRL littermates.

(B) Quantification of proportions of RORγ<sup>+</sup> Tregs in the cecum and colon of Trpv1-ADC and CTRL mice from indicated timepoints post-CNO treatment (day 1, day 7: CNO injected daily, day 13: CNO injected every other day).


(C) Quantification of proportions of RORγ<sup>+</sup> Tregs in the cecum and colon of Trpv1-ADC and CTRL mice from indicated timepoint.

(D) Quantification of proportions of Kaede red<sup>+</sup> immune cells in the descending colon from Trpv1-ADC-Kaede and littermate controls.


(E) Quantification of proportions of Ki67<sup>+</sup> cells (of RORγ<sup>+</sup> Tregs) in the cecum and colon from Trpv1-ADC and CTRL mice.

(F) Representative flow cytometric plots and quantification of geometric MFI (gMFI) of Ki67 (of B, CD4 Tconv, CD8 T, and RORγ<sup>+</sup> Treg) in the cecum and colon from Trpv1-ADC and CTRL mice.

Each symbol (A-F) represents an individual mouse; Error bars represent mean and standard deviation. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  \*\*\*;  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  (unpaired Student's t test with Holm-Sidak correction for multiple comparison). Data are representative of 3 independent experiments. n = 5-12 mice/group.



**Fig 5. scRNAseq reveals cell stress and cell activation upon nociceptor neuron activation.** (A and B) Single-cell RNA sequencing analysis of ceum immunocytes from Trpv1-ADC and CTRL mice. UMAP plot (A). Differential density plot (B). Tn: naive T cells; Tact: activated T cells. (C) Heatmap of average expression fold changes (Trpv1-ADC vs. CTRL mice, log<sub>2</sub>) of differentially expressed genes (DEGs) extracted from 7 cell clusters as indicated. T8ab: CD8a+CD8b+ T, Mac/DC: Macrophages and dendritic cells. (D and E) scRNAseq analysis of ceum Tregs from Trpv1-ADC and CTRL mice. UMAP plot (D). Proportions of different clusters and differential density plot (E). (F) Heatmap of relative expression level (log<sub>2</sub>) of differential expressed genes (DEGs) extracted from the two RORγ<sup>+</sup> Treg clusters as indicated in E from CTRL mice only. Each symbol (E) represents an individual mouse; Error bars represent mean and standard deviation. n = 2 mice/group.



**Fig 6. Trpv1+ DRG neurons, but not NG, regulate the gut Treg niche.**

(A) Schematic of intranodose ganglionic injection into *Trpv1-Cre* and control mice for targeting of AAV9<sup>hM3Dq</sup> virus to nodose/jugular ganglia.

(B) Representative images of DRG and NG of mCherry (red) and Tuj1 (gray) after intranodose injection.

(C) Quantification of ROR $\gamma$ <sup>+</sup> Treg cells in the cecum and colon from intranodose ganglionic injected *Trpv1-Cre* and control mice.

(D) Schematic of intrathecal injection into *Trpv1-Cre* and control mice for targeting of AAV9<sup>hM3Dq</sup> virus to DRG neurons.

(E) Representative images of DRG and NG of mCherry (red) and Tuj1 (gray) from intrathecally injected mice.

(F) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from intrathecally injected *Trpv1-Cre* and control mice.


(G) Schematic of resiniferatoxin (RTX) intrathecal injection for ablation of Trpv1+ DRG neurons.

(H) Representative images of DRG and NG of mCherry (red) and Tuj1 (gray) from Trpv1-ADC mice injected intrathecally with vehicle or RTX.

(I) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from Trpv1-ADC and CTRL mice with intrathecal injection of vehicle or RTX.

Each symbol (C, F, and I) represents an individual mouse; Error bars represent mean and standard deviation. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; NS, no significance (unpaired Student's t test with Holm-Sidak correction for multiple comparison). Scale Bars: 100  $\mu\text{m}$  in (B, E, and H). Data are representative of 2 independent experiments.  $n = 4-11$  mice/group.





**Fig 7. *Trpv1*+ neurons regulate the gut Treg niche via CGRP.**

(A) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from CTRL, *Trpv1*-ADC, and *Trpv1*-ADC-*Tac1*<sup>-/-</sup> mice.

(B) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from CTRL, *Trpv1*-ADC, and *Trpv1*-ADC-*Calca*<sup>-/-</sup> mice.

(C) Representative image of Foxp3<sup>+</sup> Tregs (red) in proximity to CGRP fibers (cyan) from whole mount colon tissue.

(D) Schematic of CGRP signaling through its coreceptor complex formed by RAMP1 and CLR.

(E) UMAP of *Ramp1* expression in Treg cell populations from CTRL mice.

(F) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from CTRL and *Trpv1*-ADC mice treated with vehicle or BIBN4096.

(G) Quantification of ROR $\gamma$ <sup>+</sup> Tregs in the cecum and colon from CTRL, *Trpv1*-ADC-*Foxp3CreRamp1*<sup>+/+</sup>, and *Trpv1*-ADC-*Foxp3CreRamp1*<sup>fl/fl</sup> mice.

Each symbol (A-C, and E) represents an individual mouse; Error bars represent mean and standard deviation. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; NS, no significance (unpaired Student's *t* test with Holm-Sidak correction for multiple comparison). Scale Bars: 100  $\mu$ m in (D). Data are representative of 2 independent experiments.  $n = 4$ -10 mice/group.